Onto Innovation Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 26, 2020; filed November 2, 2020. The request metadata says 2018 Q3, but the supplied filing is for 2020 Q3. Unless stated otherwise, figures below are in millions of dollars.
Business context and period comparability
Onto designs, manufactures, and supports process-control inspection, metrology, lithography, and software systems for semiconductor and advanced-packaging manufacturers. The October 2019 Rudolph–Nanometrics merger is a major comparability factor: 2020 results include Nanometrics, while 2019 comparative results include only Rudolph. The company also changed its fiscal year to a 52–53-week year ending on the Saturday closest to December 31.
Financial performance
| Metric | Q3 2020 | Q3 2019 | First nine months 2020 | First nine months 2019 |
|---|---|---|---|---|
| Revenue | $126.5 | $62.9 | $401.4 | $185.3 |
| Gross profit | $68.9 | $31.5 | $203.1 | $95.4 |
| Gross margin | 54.5% | 50.1% | 50.6% | 51.5% |
| Operating income | $9.3 | $5.3 | $12.0 | $18.3 |
| Net income | $8.1 | $6.6 | $11.1 | $19.7 |
| Diluted EPS | $0.16 | $0.26 | $0.22 | $0.78 |
| Operating cash flow | Not separately stated | Not separately stated | $72.9 | $24.9 |
- Q3 revenue increased 101% year over year, while nine-month revenue increased 117%; both comparisons are substantially affected by the merger.
- Sequentially, Q3 revenue declined 6.3% from $134.9 million in Q2, primarily because two major metrology customers had made significant equipment purchases in the first half of 2020.
- Q3 gross margin improved from Q2’s 53% to 54%, supported by stronger product margins, record service revenue, and lower merger-related expenses. Nine-month margin was pressured by $10.2 million of acquired-inventory fair-value step-up charges.
- Nine-month operating expenses were $191.1 million, including $41.1 million of intangible-asset amortization, compared with $77.1 million and $1.2 million, respectively, in the prior-year period. Amortization and inclusion of the acquired business contributed to lower year-over-year operating income and EPS despite much higher revenue.
- Q3 net income rose year over year, but diluted EPS fell, with weighted-average diluted shares increasing to 49.1 million from 25.3 million, largely reflecting the merger-related change in share base.
Cash, liquidity, and capital
- At September 26, 2020, cash and cash equivalents were $101.6 million and marketable securities were $238.8 million, totaling $340.4 million, versus $320.2 million at year-end 2019. Working capital was $579.5 million, up from $555.9 million.
- For the first nine months, operating cash flow was $72.9 million. Investing activities used $49.7 million, including $3.4 million of capital expenditures; financing activities used $53.1 million, including $52.0 million of share repurchases. Cash and cash equivalents declined by $29.1 million to $101.6 million.
- The filing reports no outstanding borrowings. A securities-secured line of credit had approximately $71.2 million available at an interest rate of 1.8%; it had not been used.
- The company repurchased 1.9 million shares for $52.0 million during the nine months and had $28.0 million remaining under its $80.0 million authorization.
- Current liabilities were $97.2 million; total liabilities were $193.0 million. The filing does not list conventional debt as an outstanding liability.
Outlook, commentary, and risks
- Management said it expects existing cash, cash equivalents, marketable securities, and available credit to cover anticipated needs for at least the next 12 months. No specific revenue or earnings guidance is provided in the supplied filing text.
- Management described semiconductor customer demand for logic and foundry capacity and smaller-node transitions, and reported launching four new metrology systems in the first nine months. It said integration activities continued and cost-synergy targets were being met or exceeded.
- Management reported no material direct financial impact from COVID-19 through the quarter, but warned that future effects could be material through demand, customer qualification and R&D delays, supply-chain disruption, added costs, and reduced credit availability.
- U.S.–China export restrictions and trade tensions could affect China sales. For the nine months, three customers represented 16.2%, 14.4%, and 7.4% of revenue, respectively; the filing highlights customer concentration as a risk.
- Foreign-exchange losses were $2.1 million for the nine months, compared with gains of $0.8 million a year earlier. The company uses non-designated currency forwards; their September 26 notional value was $33.6 million.
- In the OSI litigation, two claims were dismissed with prejudice and two others remained subject to amendment; trial was set for May 2022. Management characterized the loss contingency as remote and did not expect a material financial impact.
- Management concluded disclosure controls were effective at a reasonable-assurance level. However, Nanometrics was excluded from the controls evaluation; it represented 27% of total assets and 51% of nine-month revenue. Merger integration of financial reporting controls and ERP systems was ongoing.
Investor verification priorities
- Confirm the merger’s effect on year-over-year growth, margins, expenses, EPS, and share counts; 2019 comparisons do not include Nanometrics.
- Track customer spending concentration, particularly the timing of major metrology orders, and assess customer concentration and China exposure.
- Review cash conversion, working-capital movements, inventory levels, and the sustainability of operating cash flow.
- Monitor merger integration, expected synergies, acquired-intangible amortization, and the completion and effectiveness of internal-control integration.
- Assess developments in COVID-19, export controls and trade restrictions, supply-chain availability, foreign-exchange exposure, and the OSI case.